We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.80 | 8.44% | 48.80 | 48.00 | 49.00 | 49.00 | 45.00 | 45.00 | 5,721,464 | 16:35:17 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.51 | 137.55M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/5/2017 10:05 | Yet more good news. | the drewster | |
11/5/2017 20:36 | I have been watching the presentation by Alistair Smith of the company and their affirmer technology, and i am very impressed indeed. If any of that succeeds this a billion dollar company i reckon. Very interesting indeed. | escapetohome | |
11/5/2017 10:09 | Allegedly, doesn't a nomination for any award usually mean that you've just asked a couple of friends to put your name forward. | mrangry2 | |
11/5/2017 09:03 | They say not, and the recent announcement, despite lacking figures, must help on that score. Good to see Avacta shortlisted for Best Technology ... | the drewster | |
10/5/2017 22:33 | Do they need more money for expansion | letmepass | |
10/5/2017 16:38 | A couple of largish sells today 11:06:10 80.00 150,000 O 88.00 92.00 Sell 11:05:57 80.00 200,000 O 88.00 92.00 Sell | turbocharge | |
10/5/2017 10:07 | lots of drug development, and less red tape meaning faster to market ... certainly part of the BOOM, but more adding weight for when it finally happens. I can see affimers being hugely popular in China. | the drewster | |
10/5/2017 09:11 | This should be an attractive option in China... lots of drug development! | bonzo | |
10/5/2017 07:38 | China part of the boom? | wells777 | |
09/5/2017 13:21 | tick tick tick, but still waiting for the BOOM: Moderna releases Phase I trial data for mRNA technology By StockMarketWire | Mon, 8th May 2017 - 13:32 Avacta Group has confirmed that Moderna has disclosed Phase I trial data for its mRNA technology. It says this is the first public evidence that it works, which meaningfully de-risks the partnership plans to deliver Affimer therapeutics using mRNA. Background: Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. Moderna was the first to enter into an agreement with Avacta to use the Affimer technology, in tandem with Moderna's mRNA drug delivery platform. At 1:32pm: (LON:AVCT) Avacta Group PLC share price was -0.5p at 86p | the drewster | |
27/4/2017 04:59 | With a share price finish over the 200Sma AVCT is looking good for the long term. This should turn MrAngry2 into MrHappyToo | curnic1 | |
26/4/2017 12:53 | Wan has got things right in the past and foresaw that Carclo would come crashing down a few months ago. He seems to do a lot of research before he gives his opinion and I have a great deal of respect for him. I'm a long term investor (I bought in 2010), and I'll hold on for the time being. I'm in no hurry. | mrangry2 | |
26/4/2017 12:36 | Correct mr angry 2 , fantastic buy, long term investors dissed the share they wAited year after year for results that never came. It took their negative comments as a positive as they were trying to disguise the buying opportunity, and what an opportunity it was. | escapetohome | |
26/4/2017 12:27 | escapetohome - What a great buy for you. Up by about 25% in 7 weeks! | mrangry2 | |
25/4/2017 11:13 | Spekky...Obviously situations can change, but Avacta did not see fit to announce the resignation of Director Paul Ferrigno. What is interesting is that the founder of Affimers has not disappeared into the ether, but has recently set up two companies on his own, which also includes setting up, as a sole Director, Code Therapeutics in December 2016 - | wan | |
25/4/2017 09:41 | metaLinear metaLinear engineers microbial proteomes to identify novel targets for anti-infective drug discovery. | the drewster | |
25/4/2017 08:48 | Though trying to use charts is never easy on AIM, we're at the very top of the down channel that has plagued us for 20 months - breaking through to the upside could be the start of some stellar gains (at last). | the drewster | |
24/4/2017 12:50 | Wan........do you have any thoughts on Paul setting up at Thorpe Arch ? Metalinear Ltd. is registered to an address in Harrogate (Paul's home ??) | spekky | |
24/4/2017 12:15 | Nice very very nice , at the moment long term investors were at their most gloomy was when i came in and bought my stake, after years of their waiting. Thats the way to do it, you play this game! | escapetohome | |
24/4/2017 11:58 | Yes,this can only be good news! Let's look forward to more of it. | lantanatony | |
24/4/2017 10:45 | Yes,this can only be good news! Let's look forward to more of it. | lantanatony | |
24/4/2017 10:14 | So Abcsm likely! | bonzo | |
24/4/2017 10:14 | Likely to be a company with whom that have a close relationship already.,,, | bonzo | |
24/4/2017 09:46 | counterparty could be Abcam? | mw8156 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions